Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

Zydus Cadila Healthcare’s Desidustat has demonstrated efficacy in a phase 2b clinical trial in Mexico for COVID-19 patients hospitalized with hypoxia.

The Indian drugmaker said study results showed treatment with Desidustat boosted red blood cell production and oxygen delivery to tissues, and no participants in the Desidustat arm required mechanical ventilation vs. 25 percent in the arm receiving the standard of care.

Zydus has two ongoing phase 3 trials evaluating Desidustat for treatment of anemia linked to chronic kidney disease and chemotherapies.